Segment Information (Tables)

6 Months Ended

Jun. 30, 2024

Segment Information

Summary of results of operations by segment

(In thousands)			Contract		Corporate		Total
Three Months Ended June 30, 2024	Therapeutics		Research		and Other		Company
Revenue from external customers	$	2,141	$	625	$	—	$	2,766
Intercompany revenue		—		3,421		(3,421)		—
Cost of revenue		—		3,836		(3,212)		624
Research and development		8,870		—		(209)		8,661
General and administrative		—		1,019		3,733		4,752
Licensing		1,285		—		—		1,285
Revaluation of contingent consideration		200		—		—		200
Restructuring expense		98		—		—		98
Loss from operations	$	(8,312)	$	(809)	$	(3,733)	$	(12,854)
(In thousands)			Contract		Corporate		Total
Three Months Ended June 30, 2023	Therapeutics		Research		and Other		Company
Revenue from external customers	$	993	$	876	$	—	$	1,869
Intercompany revenue		—		4,000		(4,000)		—
Cost of revenue		—		4,796		(3,754)		1,042
Research and development		25,521		—		(246)		25,275
General and administrative		—		1,254		7,063		8,317
Licensing		550		—		—		550
Revaluation of contingent consideration		(1,500)		—		—		(1,500)
Loss from operations	$	(23,578)	$	(1,174)	$	(7,063)	$	(31,815)
(In thousands)			Contract		Corporate		Total
Six Months Ended June 30, 2024	Therapeutics		Research		and Other		Company
Revenue from external customers	$	3,882	$	1,281	$	—	$	5,163
Intercompany revenue		—		7,087		(7,087)		—
Cost of revenue		—		7,861		(6,646)		1,215
Research and development		17,427		—		(441)		16,986
General and administrative		—		2,128		8,436		10,564
Licensing		2,316		—		—		2,316
Revaluation of contingent consideration		3,000		—		—		3,000
Restructuring expense		1,618		218		1,032		2,868
Loss from operations	$	(20,479)	$	(1,839)	$	(9,468)	$	(31,786)
(In thousands)			Contract		Corporate		Total
Six Months Ended June 30, 2023	Therapeutics		Research		and Other		Company
Revenue from external customers	$	2,632	$	1,765	$	—	$	4,397
Intercompany revenue		—		8,011		(8,011)		—
Cost of revenue		—		9,343		(7,493)		1,850
Research and development		48,380		—		(518)		47,862
General and administrative		—		2,316		14,791		17,107
Licensing		1,611		—		—		1,611
Revaluation of contingent consideration		(2,300)		—		—		(2,300)
Loss from operations	$	(45,059)	$	(1,883)	$	(14,791)	$	(61,733)